Longeveron Mesenchymal Stem Cells
Phase 1Cell therapy
Longeveron Mesenchymal Stem Cells is one of 21 biologic programs targeting Hypoplastic Left Heart Syndrome. It is currently in Phase 1.
2
Indications
5
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Proventil
Mylan Pharmaceuticals IncPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
Orap
TevaPreclinical
Biological Data
UUniversity Hospital, Bordeaux
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Longeveron Mesenchymal Stem Cells
LLongeveron Inc.
Phase 1
Immunosuppressive
Chiesi Farmaceutici S.p.A.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypoplastic Left Heart Syndrome1 trial
Mesenchymal Stem Cells1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- LLongeveron Inc.